Clinical Trial 55250

Walnut Creek, CA 94598


Summary:

The purpose of this Phase IIIb study is to evaluate the efficacy and safety of budesonide/albuterol 160/180 μg metered-dose inhaler [MDI]; XXXX; BDA MDI, used as needed in participants with asthma previously receiving short-acting β2-agonists (SABA) alone or SABA as needed plus on a background of either low-dose inhaled corticosteroids (ICS) or a leukotriene receptor antagonist (LTRA). The rationale for BDA MDI to be used as a rescue therapy is based on the provision of rapid relief of asthma symptoms by albuterol while simultaneously treating underlying inflammation with budesonide. Use of BDA MDI will be driven by day-to-day symptom levels and will follow a patient’s natural behavior to treat symptoms when they arise and thus treatment for inflammation will be provided when needed most. Safety and efficacy of BDA MDI will be compared with albuterol (XXXX; AS MDI) because albuterol is the standard of care rescue therapy in the United States (US).

 

Participant must

  • Be ≥12 years of age.
  • Have diagnosis of asthma by a prescribing healthcare professional. 

  • Be capable of giving signed eICF (including assent with parental / legal guardian consent in 12 to < 18 year olds)

  • Have no evidence of significant lung disease other than asthma.

  • California residents only

  • Note: this study is 100% virtual (no commute to the clinic is necessary. Visit will be completed like telehealth).


Qualified Participants May Receive:

Stipend of $50 per visit completed.

 


Available At:

Virtual, Remote

 


If you or someone you care for is interested in participating and lives within 50 miles of the location shown, please complete the form below and click 'Submit'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.